Sarepta CEO Change After a 90% Crash; What Went Wrong?
Severino replaces longtime CEO Doug Ingram and brings leadership experience from Tessera Therapeutics and AbbVie. Sarepta presented the appointment as a new phase for its precision genetic medicine strategy. However, Severino inherits more than a commercial recovery challenge. He must lead a company that faced intense scrutiny after fatal acute liver failure reports involving AAVrh74-based gene therapies and major questions about how management communicated safety information.
Sarepta CEO Change Faces Its First Test; Can Quality Culture Recover?
A new chief executive can change priorities, but leadership alone cannot restore trust. Sarepta must show that patient safety, transparent escalation and regulatory cooperation guide daily decisions across clinical development, pharmacovigilance and quality governance.
Therefore, the company’s recovery will depend on how leaders handle adverse-event signals, challenge assumptions and communicate uncertainty. A strong quality culture allows teams to escalate uncomfortable information before commercial or investor pressure shapes the response. In contrast, weak escalation pathways can turn a safety signal into a wider credibility crisis.
A Patient Death Went Undisclosed; Sarepta’s Regulatory Trust Took the Hit
In July 2025, Sarepta faced criticism after it did not publicly discuss the death of a patient in an SRP-9004 limb-girdle muscular dystrophy study during a restructuring update. The company said it had reported the life-threatening event and subsequent death to the FDA within required timelines. Still, then-CEO Doug Ingram said the company had not viewed the death as material or central to that investor discussion.
That distinction did not end the controversy. Instead, it raised a broader question for regulated companies: meeting formal reporting duties does not always meet stakeholder expectations for transparency. In high-risk therapies, communication decisions can directly influence regulatory relationships, patient confidence and corporate credibility.
Gene Therapy Safety Crisis Deepens; Sarepta’s New CEO Inherits the Risk
The FDA reported three fatal acute liver failure cases following treatment with Sarepta’s AAVrh74 gene therapies. Consequently, the agency requested a distribution suspension for Elevidys and placed several clinical trials on hold. Later, the FDA restricted the Elevidys indication and required stronger safety warnings.
As a result, Severino must strengthen the connection between safety surveillance, medical governance, quality risk management and executive decisions. He must also maintain clear oversight as Sarepta advances new programs. Gene therapy companies cannot separate regulatory trust from the speed, quality and transparency of their safety responses.
Can Sarepta Rebuild Regulatory Trust; Or Is the Damage Already Done?
Sarepta’s next milestones will show whether this appointment represents a leadership reset or only a change at the top. Investors will watch pipeline progress, but regulators and quality professionals will focus on evidence quality, safety escalation, disclosure practices and management accountability.
Zamann Pharma’s Quality Management System service helps pharmaceutical teams strengthen deviation management, CAPA, change control, internal audits and quality governance during high-risk organizational change. Explore structured QMS support to improve operational control and build a quality culture that protects both compliance and patient trust.
Source: Endpoints.News.Com